Dr. Mewawalla speaks to oncologists, care teams, and patient communities about how to choose, sequence, and safely deliver CAR T-cell therapy and bispecific antibodies, including beyond major academic centers.
2026 · Leading a conference on clinician wellness, sponsored by the AHN Women Physicians ERG.
Videos & Media
Video & media library.
A complete, searchable library of Dr. Mewawalla's public video and media appearances in multiple myeloma and cellular therapy, including two CancerNetwork video series, national oncology-media interviews, and educational videos. Every title links to the original publisher. Search or filter by topic, publisher, and year.
Showing all 25 entries (39 recordings across 2 series and 23 videos).
CancerNetwork
CancerNetwork series · Bispecific antibodies · R/R myeloma
Evolving Treatment Strategies in Relapsed/Refractory Multiple Myeloma: Integrating Bispecific Antibodies Into Earlier Lines of Care
A 14-part expert video series on defining anti-CD38–refractory disease, selecting and sequencing BCMA-directed bispecific antibodies and CAR T-cell therapy, interpreting MajesTEC data, and managing safety across patient populations.
Around the Practice · CAR T-cell therapy · R/R myeloma
Ciltacabtagene Autoleucel in Multiple Myeloma: Optimizing Sequencing, Safety Management, and Care Team Communication
A CancerNetwork Around the Practice program with Surbhi Sidana, MD, Doris Hansen, MD, and Dr. Mewawalla on where cilta-cel belongs in sequencing and how to individualize CAR T-cell therapy versus bispecific antibodies in relapsed multiple myeloma. New episodes are being added as the series continues.
Presenting the most important practice-changing advances in multiple myeloma. "What makes these meetings valuable is not just discussing new developments, it is examining how we translate that evidence into better treatment selection, thoughtful sequencing, and meaningful outcomes for our patients."
On the podium
Recent invited presentations across national myeloma and cellular therapy meetings.
Course Director, Highlights of ASH® 2025."Advances in CAR T-cell Therapy for Multiple Myeloma", ICE-T Congress (Univ. of Kansas Medical Center).Presenting MAGNETISMM-3 (elranatamab) data, International Cell Effector Therapy Congress.Best of ASCO® 2026, Pittsburgh, practice-changing advances in myeloma.Invited speaker, Fairmont Pittsburgh.Presenting at the Omni William Penn Hotel, Pittsburgh.
Invited faculty, Best of ASCO® 2026, Practice-Changing Advances in Multiple Myeloma and AL Amyloidosis.
On panels and main stages
Panel discussions and plenary sessions at national meetings.
Panel discussion on a national main stage.Faculty panelist at a national conference.On stage before a full conference audience.
Audiences & Formats
Who she speaks to, and how.
Audiences
Community & academic oncologists · advanced-practice providers & nursing · tumor boards & grand rounds · patient & caregiver groups · industry medical/scientific meetings.
